140 related articles for article (PubMed ID: 17440020)
1. Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial.
Reid IR; Cundy T; Grey AB; Horne A; Clearwater J; Ames R; Orr-Walker BJ; Wu F; Evans MC; Gamble GD; King A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2446-52. PubMed ID: 17440020
[TBL] [Abstract][Full Text] [Related]
2. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
Alexandersen P; Riis BJ; Christiansen C
J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
[TBL] [Abstract][Full Text] [Related]
3. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
[TBL] [Abstract][Full Text] [Related]
4. Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate.
Ringe JD; Kipshoven C; Cöster A; Umbach R
Osteoporos Int; 1999; 9(2):171-8. PubMed ID: 10367046
[TBL] [Abstract][Full Text] [Related]
5. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
Reginster JY; Meurmans L; Zegels B; Rovati LC; Minne HW; Giacovelli G; Taquet AN; Setnikar I; Collette J; Gosset C
Ann Intern Med; 1998 Jul; 129(1):1-8. PubMed ID: 9652994
[TBL] [Abstract][Full Text] [Related]
6. Monofluorophosphate combined with hormone replacement therapy in postmenopausal osteoporosis. An open-label pilot efficacy and safety study.
Ringe JD; Setnikar I
Rheumatol Int; 2002 May; 22(1):27-32. PubMed ID: 12120908
[TBL] [Abstract][Full Text] [Related]
7. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride.
Delmas PD; Dupuis J; Duboeuf F; Chapuy MC; Meunier PJ
J Bone Miner Res; 1990 Mar; 5 Suppl 1():S143-7. PubMed ID: 2339624
[TBL] [Abstract][Full Text] [Related]
8. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
[TBL] [Abstract][Full Text] [Related]
9. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
Bone HG; Downs RW; Tucci JR; Harris ST; Weinstein RS; Licata AA; McClung MR; Kimmel DB; Gertz BJ; Hale E; Polvino WJ
J Clin Endocrinol Metab; 1997 Jan; 82(1):265-74. PubMed ID: 8989272
[TBL] [Abstract][Full Text] [Related]
10. Low-dose fluoride in postmenopausal women: a randomized controlled trial.
Grey A; Garg S; Dray M; Purvis L; Horne A; Callon K; Gamble G; Bolland M; Reid IR; Cundy T
J Clin Endocrinol Metab; 2013 Jun; 98(6):2301-7. PubMed ID: 23553866
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
12. [The treatment of vertebral osteoporosis. Use of sodium fluoride and sodium monofluorophosphate in combination with calcium].
Meunier PJ
Fortschr Med; 1990 Jan; 108(1):45-8. PubMed ID: 2179080
[TBL] [Abstract][Full Text] [Related]
13. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
Meunier PJ; Sebert JL; Reginster JY; Briancon D; Appelboom T; Netter P; Loeb G; Rouillon A; Barry S; Evreux JC; Avouac B; Marchandise X
Osteoporos Int; 1998; 8(1):4-12. PubMed ID: 9692071
[TBL] [Abstract][Full Text] [Related]
14. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis.
Haguenauer D; Welch V; Shea B; Tugwell P; Adachi JD; Wells G
Osteoporos Int; 2000; 11(9):727-38. PubMed ID: 11148800
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures.
Gutteridge DH; Stewart GO; Prince RL; Price RI; Retallack RW; Dhaliwal SS; Stuckey BG; Drury P; Jones CE; Faulkner DL; Kent GN; Bhagat CI; Nicholson GC; Jamrozik K
Osteoporos Int; 2002; 13(2):158-70. PubMed ID: 11908491
[TBL] [Abstract][Full Text] [Related]
16. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study.
Guaydier-Souquières G; Kotzki PO; Sabatier JP; Basse-Cathalinat B; Loeb G
Osteoporos Int; 1996; 6(2):171-7. PubMed ID: 8704358
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
18. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate.
Ringe JD; Dorst A; Kipshoven C; Rovati LC; Setnikar I
Osteoporos Int; 1998; 8(1):47-52. PubMed ID: 9692077
[TBL] [Abstract][Full Text] [Related]
19. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.
Riggs BL; Hodgson SF; O'Fallon WM; Chao EY; Wahner HW; Muhs JM; Cedel SL; Melton LJ
N Engl J Med; 1990 Mar; 322(12):802-9. PubMed ID: 2407957
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
